CAS
PTCT icon

Coppell Advisory Solutions’s PTC Therapeutics PTCT Stock Holding History

Coppell Advisory Solutions’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-533
Closed -$24.4K – 1473
2024
Q4 		$24.4K Buy
+533
New +$22.8K ﹤0.01% 796

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coppell Advisory Solutions's PTCT Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of PTC Therapeutics (PTCT) in Q1 2025, closing a stake of 533 shares — an estimated $24.4K sold.

Coppell Advisory Solutions first reported a position in PTCT in Q4 2024 and held it in 1 quarter. The position peaked at $24.4K in Q4 2024. 260 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining PTC Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 533 PTC Therapeutics shares in Q1 2025, an estimated $24.4K.
  • Coppell Advisory Solutions first reported a position in PTC Therapeutics in Q4 2024 and held it in 1 quarter.
  • Coppell Advisory Solutions's PTC Therapeutics position peaked at $24.4K in Q4 2024.
  • 260 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.